This review discusses how beta-glucans interact with Dectin-1, complement receptor 3, and TLR2/6 and thereby influence macrophages, neutrophils, monocytes, natural-killer cells, and dendritic cells. It also summarizes proposed oral uptake and fragmentation pathways and cancer-related laboratory and animal evidence. The article emphasizes mechanisms and preclinical observations; it does not demonstrate that beta-glucan treats cancer in humans or that different source materials are interchangeable.
Review of beta-glucan receptors, immune-cell responses, oral processing, and cancer-related research.
Mechanistic and preclinical evidence cannot establish human cancer treatment efficacy or equivalence across glucan sources.
AI-generated summary for accessibility. Always refer to the original paper.
Chan, Godfrey Chi-Fung; Chan, Wing Keung; Sze, Daniel Man-Yuen. The effects of β-glucan on human immune and cancer cells. Journal of Hematology & Oncology. 2009. DOI: 10.1186/1756-8722-2-25.
For scientific reference only. Not medical advice. Consult a qualified healthcare professional. See our Medical Disclaimer.